209 related articles for article (PubMed ID: 34644147)
1. Epigenetically defined therapeutic targeting in H3.3G34R/V high-grade gliomas.
Sweha SR; Chung C; Natarajan SK; Panwalkar P; Pun M; Ghali A; Bayliss J; Pratt D; Shankar A; Ravikumar V; Rao A; Cieslik M; Wilder-Romans K; Scott AJ; Wahl DR; Jessa S; Kleinman CL; Jabado N; Mackay A; Jones C; Martinez D; Santi M; Judkins AR; Yadav VN; Qin T; Phoenix TN; Koschmann CJ; Baker SJ; Chinnaiyan AM; Venneti S
Sci Transl Med; 2021 Oct; 13(615):eabf7860. PubMed ID: 34644147
[TBL] [Abstract][Full Text] [Related]
2. Dissecting the impact of regional identity and the oncogenic role of human-specific NOTCH2NL in an hESC model of H3.3G34R-mutant glioma.
Funato K; Smith RC; Saito Y; Tabar V
Cell Stem Cell; 2021 May; 28(5):894-905.e7. PubMed ID: 33631117
[TBL] [Abstract][Full Text] [Related]
3. Effects of H3.3G34V mutation on genomic H3K36 and H3K27 methylation patterns in isogenic pediatric glioma cells.
Huang TY; Piunti A; Qi J; Morgan M; Bartom E; Shilatifard A; Saratsis AM
Acta Neuropathol Commun; 2020 Dec; 8(1):219. PubMed ID: 33287886
[TBL] [Abstract][Full Text] [Related]
4. Novel genetically engineered H3.3G34R model reveals cooperation with ATRX loss in upregulation of
Abdallah AS; Cardona HJ; Gadd SL; Brat DJ; Powla PP; Alruwalli WS; Shen C; Picketts DJ; Li XN; Becher OJ
Neurooncol Adv; 2023; 5(1):vdad003. PubMed ID: 36845293
[TBL] [Abstract][Full Text] [Related]
5. RACK7 recognizes H3.3G34R mutation to suppress expression of MHC class II complex components and their delivery pathway in pediatric glioblastoma.
Jiao F; Li Z; He C; Xu W; Yang G; Liu T; Shen H; Cai J; Anastas JN; Mao Y; Yu Y; Lan F; Shi YG; Jones C; Xu Y; Baker SJ; Shi Y; Guo R
Sci Adv; 2020 Jul; 6(29):eaba2113. PubMed ID: 32832624
[TBL] [Abstract][Full Text] [Related]
6. Invited Review: Emerging functions of histone H3 mutations in paediatric diffuse high-grade gliomas.
Kasper LH; Baker SJ
Neuropathol Appl Neurobiol; 2020 Feb; 46(1):73-85. PubMed ID: 31859390
[TBL] [Abstract][Full Text] [Related]
7. A Compendium of Syngeneic, Transplantable Pediatric High-Grade Glioma Models Reveals Subtype-Specific Therapeutic Vulnerabilities.
McNicholas M; De Cola A; Bashardanesh Z; Foss A; Lloyd CB; Hébert S; Faury D; Andrade AF; Jabado N; Kleinman CL; Pathania M
Cancer Discov; 2023 Jul; 13(7):1592-1615. PubMed ID: 37011011
[TBL] [Abstract][Full Text] [Related]
8. Pediatric glioma histone H3.3 K27M/G34R mutations drive abnormalities in PML nuclear bodies.
Voon HPJ; Hii L; Garvie A; Udugama M; Krug B; Russo C; Chüeh AC; Daly RJ; Morey A; Bell TDM; Turner SJ; Rosenbluh J; Daniel P; Firestein R; Mann JR; Collas P; Jabado N; Wong LH
Genome Biol; 2023 Dec; 24(1):284. PubMed ID: 38066546
[TBL] [Abstract][Full Text] [Related]
9. Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis.
Chen CCL; Deshmukh S; Jessa S; Hadjadj D; Lisi V; Andrade AF; Faury D; Jawhar W; Dali R; Suzuki H; Pathania M; A D; Dubois F; Woodward E; Hébert S; Coutelier M; Karamchandani J; Albrecht S; Brandner S; De Jay N; Gayden T; Bajic A; Harutyunyan AS; Marchione DM; Mikael LG; Juretic N; Zeinieh M; Russo C; Maestro N; Bassenden AV; Hauser P; Virga J; Bognar L; Klekner A; Zapotocky M; Vicha A; Krskova L; Vanova K; Zamecnik J; Sumerauer D; Ekert PG; Ziegler DS; Ellezam B; Filbin MG; Blanchette M; Hansford JR; Khuong-Quang DA; Berghuis AM; Weil AG; Garcia BA; Garzia L; Mack SC; Beroukhim R; Ligon KL; Taylor MD; Bandopadhayay P; Kramm C; Pfister SM; Korshunov A; Sturm D; Jones DTW; Salomoni P; Kleinman CL; Jabado N
Cell; 2020 Dec; 183(6):1617-1633.e22. PubMed ID: 33259802
[TBL] [Abstract][Full Text] [Related]
10. EGFR promoter exhibits dynamic histone modifications and binding of ASH2L and P300 in human germinal matrix and gliomas.
Erfani P; Tome-Garcia J; Canoll P; Doetsch F; Tsankova NM
Epigenetics; 2015; 10(6):496-507. PubMed ID: 25996283
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic activation of a RAS/MYC axis in H3.3K27M-driven cancer.
Pajovic S; Siddaway R; Bridge T; Sheth J; Rakopoulos P; Kim B; Ryall S; Agnihotri S; Phillips L; Yu M; Li C; Milos S; Patel P; Srikanthan D; Huang A; Hawkins C
Nat Commun; 2020 Dec; 11(1):6216. PubMed ID: 33277484
[TBL] [Abstract][Full Text] [Related]
12. Targeting Epigenetic Pathways in the Treatment of Pediatric Diffuse (High Grade) Gliomas.
Vanan MI; Underhill DA; Eisenstat DD
Neurotherapeutics; 2017 Apr; 14(2):274-283. PubMed ID: 28233220
[TBL] [Abstract][Full Text] [Related]
13. Oncohistone interactome profiling uncovers contrasting oncogenic mechanisms and identifies potential therapeutic targets in high grade glioma.
Siddaway R; Canty L; Pajovic S; Milos S; Coyaud E; Sbergio SG; Vadivel Anguraj AK; Lubanszky E; Yun HY; Portante A; Carette S; Zhang C; Moran MF; Raught B; Campos EI; Hawkins C
Acta Neuropathol; 2022 Nov; 144(5):1027-1048. PubMed ID: 36070144
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic-Targeted Treatments for H3K27M-Mutant Midline Gliomas.
Lu VM; Daniels DJ
Adv Exp Med Biol; 2021; 1283():73-84. PubMed ID: 33155139
[TBL] [Abstract][Full Text] [Related]
15. Genetic and clinical characterization of B7-H3 (CD276) expression and epigenetic regulation in diffuse brain glioma.
Wang Z; Wang Z; Zhang C; Liu X; Li G; Liu S; Sun L; Liang J; Hu H; Liu Y; Zhang W; Jiang T
Cancer Sci; 2018 Sep; 109(9):2697-2705. PubMed ID: 30027617
[TBL] [Abstract][Full Text] [Related]
16. Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas.
Fontebasso AM; Schwartzentruber J; Khuong-Quang DA; Liu XY; Sturm D; Korshunov A; Jones DT; Witt H; Kool M; Albrecht S; Fleming A; Hadjadj D; Busche S; Lepage P; Montpetit A; Staffa A; Gerges N; Zakrzewska M; Zakrzewski K; Liberski PP; Hauser P; Garami M; Klekner A; Bognar L; Zadeh G; Faury D; Pfister SM; Jabado N; Majewski J
Acta Neuropathol; 2013 May; 125(5):659-69. PubMed ID: 23417712
[TBL] [Abstract][Full Text] [Related]
17. Pervasive H3K27 Acetylation Leads to ERV Expression and a Therapeutic Vulnerability in H3K27M Gliomas.
Krug B; De Jay N; Harutyunyan AS; Deshmukh S; Marchione DM; Guilhamon P; Bertrand KC; Mikael LG; McConechy MK; Chen CCL; Khazaei S; Koncar RF; Agnihotri S; Faury D; Ellezam B; Weil AG; Ursini-Siegel J; De Carvalho DD; Dirks PB; Lewis PW; Salomoni P; Lupien M; Arrowsmith C; Lasko PF; Garcia BA; Kleinman CL; Jabado N; Mack SC
Cancer Cell; 2019 May; 35(5):782-797.e8. PubMed ID: 31085178
[TBL] [Abstract][Full Text] [Related]
18. Histone H3.3K27M Mobilizes Multiple Cancer/Testis (CT) Antigens in Pediatric Glioma.
Deng H; Zeng J; Zhang T; Gong L; Zhang H; Cheung E; Jones C; Li G
Mol Cancer Res; 2018 Apr; 16(4):623-633. PubMed ID: 29453317
[TBL] [Abstract][Full Text] [Related]
19. H3-K27M-mutant nucleosomes interact with MLL1 to shape the glioma epigenetic landscape.
Furth N; Algranati D; Dassa B; Beresh O; Fedyuk V; Morris N; Kasper LH; Jones D; Monje M; Baker SJ; Shema E
Cell Rep; 2022 May; 39(7):110836. PubMed ID: 35584667
[TBL] [Abstract][Full Text] [Related]
20. Investigating crosstalk between H3K27 acetylation and H3K4 trimethylation in CRISPR/dCas-based epigenome editing and gene activation.
Zhao W; Xu Y; Wang Y; Gao D; King J; Xu Y; Liang FS
Sci Rep; 2021 Aug; 11(1):15912. PubMed ID: 34354157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
